Loading...
XSHE
300015
Market cap16bUSD
Apr 03, Last price  
13.37CNY
1D
0.83%
1Q
7.05%
Jan 2017
0.60%
IPO
3.89%
Name

Aier Eye Hospital Group Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
36.79
P/S
6.07
EPS
0.36
Div Yield, %
1.12%
Shrs. gr., 5y
6.43%
Rev. gr., 5y
20.52%
Revenues
20.37b
+26.43%
191,188,834314,903,815439,120,734606,450,103864,877,4501,310,624,4721,640,130,4501,984,967,2872,402,047,6163,165,580,4714,000,401,6715,962,845,5598,008,573,9549,990,103,97611,912,409,98415,000,809,43816,109,946,68720,367,156,738
Net income
3.36b
+33.07%
14,591,52138,979,51661,366,55592,489,402120,309,791171,927,760182,546,813223,495,554309,186,277428,043,981557,467,244742,514,5371,008,937,3481,378,920,9701,723,805,3352,323,343,9572,524,230,8403,358,871,535
CFO
5.87b
+30.76%
36,904,48992,187,299121,174,149169,137,874239,966,170257,108,449301,818,986412,651,458453,683,706522,168,231675,098,1661,330,404,5121,399,870,3982,078,432,7343,343,611,3254,084,103,9584,490,674,8115,871,890,091
Dividend
Jun 06, 20240.15002 CNY/sh
Earnings
Apr 24, 2025

Profile

Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. The company operates approximately 500 ophthalmic hospitals in mainland China, 86 ophthalmic hospitals in Europe, 1 ophthalmic hospital in the United States, 7 ophthalmic hospitals in Hong Kong, and 12 ophthalmic hospitals in Southeast Asia. The company was founded in 2007 and is headquartered in Changsha, China.
URL
https://www.aierchina.com/
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
20,367,157
26.43%
16,109,947
7.39%
Cost of revenue
12,958,718
10,306,961
Unusual Expense (Income)
NOPBT
7,408,438
5,802,985
NOPBT Margin
36.37%
36.02%
Operating Taxes
895,023
646,059
Tax Rate
12.08%
11.13%
NOPAT
6,513,415
5,156,926
Net income
3,358,872
33.07%
2,524,231
8.65%
Dividends
(717,651)
(648,731)
Dividend yield
0.49%
0.29%
Proceeds from repurchase of equity
(564,655)
2,389
BB yield
0.39%
0.00%
Debt
Debt current
850,367
1,111,973
Long-term debt
7,941,074
6,771,035
Deferred revenue
1
1
Other long-term liabilities
45,591
33,750
Net debt
1,087,906
498,542
Cash flow
Cash from operating activities
5,871,890
4,490,675
CAPEX
(1,459,709)
Cash from investing activities
Cash from financing activities
(2,509,722)
390,433
FCF
5,083,223
4,108,946
Balance
Cash
6,910,250
6,904,226
Long term investments
793,283
480,241
Excess cash
6,685,176
6,578,969
Stockholders' equity
18,877,450
14,100,780
Invested Capital
18,217,169
15,470,143
ROIC
38.67%
36.90%
ROCE
29.60%
26.18%
EV
Common stock shares outstanding
9,250,541
9,229,247
Price
15.82
-33.81%
23.90
-43.47%
Market cap
146,343,563
-33.65%
220,571,420
-42.38%
EV
148,740,534
222,013,957
EBITDA
9,073,935
6,969,212
EV/EBITDA
16.39
31.86
Interest
194,823
177,647
Interest/NOPBT
2.63%
3.06%